Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 187

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

ARID1A gene mutation in ovarian and endometrial cancers (Review)

Open access
TAKEDA, TAKASHI, BANNO, KOUJI, OKAWA, RYUICHIRO, YANOKURA, MEGUMI, IIJIMA, MOITO, IRIE-KUNITOMI, HARUKO, NAKAMURA, KANAKO, IIDA, MIHO, ADACHI, MASATAKA, UMENE, KIYOKO, NOGAMI, YUYA, MASUDA, KENTA, KOBAYASHI, YUSUKE, TOMINAGA, EIICHIRO, AOKI, DAISUKE · 2016 · Oncology Reports

Abstract

The AT-rich interacting domain‑containing protein 1A gene (ARID1A) encodes ARID1A, a member of the SWI/SNF chromatin remodeling complex. Mutation of ARID1A induces changes in expression of multiple genes (CDKN1A, SMAD3, MLH1 and PIK3IP1) via chromatin remodeling dysfunction, contributes to carcinogenesis, and has been shown to cause transformation of cells in association with the PI3K/AKT pathway. Information on ARID1A has emerged from comprehensive genome‑wide analyses with next‑generation sequencers. ARID1A mutations have been found in various types of cancer and occur at high frequency in endometriosis‑associated ovarian cancer, including clear cell adenocarcinoma and endometrioid adenocarcinoma, and also occur at endometrial cancer especially in endometrioid adenocarcinoma. It has also been suggested that ARID1A mutation occurs at the early stage of canceration from endometriosis to endometriosis‑associated carcinoma in ovarian cancer and also from atypical endometrial hyperplasia to endometrioid adenocarcinoma in endometrial cancer. Therefore, development of a screening method that can detect mutations of ARID1A and activation of the PI3K/AKT pathway might enable early diagnosis of endometriosis‑associated ovarian cancers and endometrial cancers. Important results may also emerge from a current clinical trial examining a multidrug regimen of temsirolimus, a small molecule inhibitor of the PI3K/AKT pathway, for treatment of advanced ovarian clear cell adenocarcinoma with ARID1A mutation and PI3K/AKT pathway activation. Also administration of sorafenib, a multikinase inhibitor, can inhibit cancer proliferation with PIK3CA mutation and resistance to mTOR inhibitors and GSK126, a molecular‑targeted drug can inhibit proliferation of ARID1A‑mutated ovarian clear cell adenocarcinoma cells by targeting and inhibiting EZH2. Further studies are needed to determine the mechanism of chromatin remodeling dysregulation initiated by ARID1A mutation, to develop methods for early diagnosis, to investigate new cancer therapy targeting ARID1A, and to examine the involvement of ARID1A mutations in development, survival and progression of cancer cells.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3892/or.2015.4421

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 187

Metadata

Authors
TAKEDA, T., BANNO, K., OKAWA, R., YANOKURA, M., IIJIMA, M., IRIE-KUNITOMI, H., NAKAMURA, K., IIDA, M., ADACHI, M., UMENE, K., NOGAMI, Y., MASUDA, K., KOBAYASHI, Y., TOMINAGA, E., & AOKI, D.
Venue
Oncology Reports
Published
2015-11-16
Volume
35
Issue
2
Pages
607-613
ISSN
  • 1021-335X (ISSN-L)
  • 1791-2431
OpenAlex
W2174510671
Cited by
187
References
6
FWCI
5.02
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: ARID1A gene mutation in ovarian and endometrial cancers (Review). https://app.cochat.ai/papers/10.3892/or.2015.4421
The paper
TAKEDA, T., BANNO, K., OKAWA, R., YANOKURA, M., IIJIMA, M., IRIE-KUNITOMI, H., NAKAMURA, K., IIDA, M., ADACHI, M., UMENE, K., NOGAMI, Y., MASUDA, K., KOBAYASHI, Y., TOMINAGA, E., & AOKI, D. (2016). ARID1A gene mutation in ovarian and endometrial cancers (Review). Oncology Reports. https://doi.org/10.3892/or.2015.4421

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.